Health Awareness (United States)

Diseases know no borders; neither should the solutions. - Sir George Alleyne, Address to the Pan American Health Organization, 1998China’s rapid expansion in pharmaceutical innovation has prompted analyses that variously portray this rise as a geographic shift, a regulatory challenge, or a geopolitical threat. Drawing on recent contributions from Kinch et al., Vokinger et al., Gautam, and Gottlieb, this commentary examines how broader discussions of China’s rise often conflate geography with geopolitics, obscuring the more consequential structural transformation underway in global drug discovery, development, and regulation.China’s ascent reflects regulatory reform, AI‑enabled discovery, and the out‑licensing of high‑value clinical assets that increasingly shape multinational R&D pipelines. Although geopolitical tensions around data integrity and market access are real, they should not eclipse opportunities for regulatory cooperation, shared standards, and improved patient access. Meanwhile, US vulnerabilities arise less from China’s progress than from domestic policy decisions that weaken scientific capacity and global health partnerships.A structural, evidence‑based framing, rather than one rooted in rivalry, offers a more constructive foundation for policy, emphasizing regulatory quality and sustained investment in US biomedical infrastructure. The organizing principle for global drug innovation should be health, not geopolitical competition.

Awareness Integration Therapy (AIT) had been documented as a multi-modality psychotherapeutic approach to improve self-awareness, dissolve past traumas and psychological blocks, and cultivate adaptive thinking conducive to learning how to improve self efficiency. The present report highlights the objective neurophysiological outcomes of AIT in a case study. The AIT-recipient was a 28 year-old Filipino female living in Dubai, UAE who presented with relationship-based concerns and anxiety-related symptoms. Over a single-session AIT, the real-time neurobiomarkers were tracked multimodally using established neurophysiological diagnostics. The study also used a 21-channel qEEG (pre-post), focused transcranial Doppler (fTCD) screening, and real-time autonomic nervous system (ANS) biosignal monitoring. Additionally, qualitative subjective outcomes of AIT were assessed for collective analysis. Findings demonstrated that both subjective emotional processing and objective biomarkers of cognitive-affective regulation had a meaningful change during and after the therapeutic intervention. The present case study suggests the viability of using AIT in psychotherapy and encourages its use in future clinical settings, especially when paired with neurophysiological monitoring. Well designed randomized control trials are needed to systematically assess its neurobehavioral substrates in clinical settings.

Network and conventional meta-analyses can increase precision for clinical decision-making but risk producing misleading hierarchies when they pool ineffective, unsafe, or unapproved dosing regimens alongside licensed therapies. Using recent evidence syntheses in alopecia areata, we show how inclusion of small, underpowered dose strata and regimens that never advanced to pivotal trials or were not pursued for regulatory approval (for example, deuruxolitinib 4 mg twice‑daily {BID}, deuruxolitinib 12 mg BID, and ritlecitinib 200 mg loading doses) can distort pooled efficacy and safety estimates, elevate unapproved regimens in rankings, and invite inappropriate causal inferences. We outline key methodological safeguards and offer concrete recommendations as follows: prespecify exclusion or planned sensitivity analyses for unapproved doses, transparently report approval status and relevant regulatory actions (for example, clinical holds) alongside pooled safety estimates, avoid causal attributions from small strata and present uncertainty appropriately, and report sensitivity analyses that omit unapproved doses. Implementing these practices preserves the statistical advantages of meta-analysis while protecting clinicians, guideline panels, and payors from misleading inferences drawn from small or unrepresentative dose groups.

To map the risk profile of drug classes at the population level by identifying associations between newly prescribed reimbursed drugs and sudden cardiac arrest (SCA), thereby providing a systematic basis for assessing individual drug effects. Population-based, matched case-control study. Greater Vienna area, Austria, using linked data from the Austrian Healthcare Reimbursement Database and the Vienna Ambulance Service between 2013 and 2020. A total of 31 330 insured individuals were included from an estimated 14 448 612 person-years at risk. Cases (n=6266) were patients with SCA, each matched 1:4 to controls (n=25 064) without SCA by age, sex and event date. The estimated absolute case risk equals 43.4 per 100 000 person-years. Newly prescribed reimbursed drugs within 4 weeks before the SCA event, classified according to four-digit Anatomical Therapeutic Chemical (ATC) codes. Associations between newly prescribed drug classes and SCA, estimated using conditional logistic regression and expressed as ORs with 95% CIs, adjusted for comorbidities and concomitant medications prescribed 120-29 days before the event. Among 322 relevant ATC drug classes, 245 were newly prescribed within 28 days prior to the SCA event. Of these, 57 (23%) were significantly associated with SCA. Eight drug classes demonstrated a markedly elevated risk (OR≥10), including oripavine derivatives (OR 64, 95% CI 8 to 486), other cardiac preparations (OR 22, 95% CI 2 to 204), plain antiandrogens (OR 18, 95% CI 1.2 to 275) and phenylpiperidine derivatives (OR 16, 95% CI 7 to 38). The most frequently prescribed associated drug classes were penicillins with beta-lactamase inhibitors (179 cases; OR 2.17, 95% CI 1.8 to 2.7), pyrazolones (167 cases; OR 2.14, 95% CI 1.7 to 2.7) and adrenergics combined with anticholinergics (130 cases; OR 2.94, 95% CI 2.2 to 3.9). Numerous outpatient-prescribed drug classes were associated with SCA. This exploratory, population-based analysis provides a systematic map of potential safety signals to inform more detailed pharmaco-epidemiological investigations, in which confounding and causality can be examined more rigorously.

Medication‑based recovery (MBR) is based on a recent proposal by leading addiction scientists, which rejects abstinence‑only definitions that drive unsafe practices such as forced tapering or discharge. Instead, it reframes opioid use disorder (OUD) treatment by recognizing that recovery can be achieved and sustained while patients remain on medication for OUD (MOUD). MBR is structured around a staged care pathway of protection, remission, and recovery, prioritizing immediate harm reduction, sustained clinical engagement, and measurable improvements in health and social functioning. It endorses ongoing MOUD combined with validated monitoring, behavioral interventions, and social supports to reduce overdose, infectious complications, and other harms.Effective implementation of MBR requires an aligned policy and payment reforms to support measurement‑based practice, coordinated services and integrated delivery, licensing and credentialing changes to protect clinicians who provide evidence‑based MOUD, and workforce development to expand prescribers and embed addiction expertise in primary care and telehealth. MBR also requires public and family education to reduce stigma and to reframe expectations about what constitutes meaningful recovery. Success should be measured by retention on MOUD and reductions in overdose risk during the protection phase, decreases in use and symptom severity during remission, and gains in housing, employment, and social functioning during recovery.Framed as both a clinical and an epistemic imperative, MBR affirms the legitimacy of evidence‑based care and counters epistemic exclusion that marginalizes patients and clinicians who rely on MOUD. Widespread adoption of MBR holds the promise of reducing mortality, improving health, and expanding equitable recovery opportunities for patients and families.

يستهدف البحث تحديد دور الإرشاد الزراعي في نشر الوعي بين مربي الماشية بالتكنولوجيا الجديدة من خلال تحقيق الأهداف الفرعية التالية: تحديد مستوى معرفة مربي الماشية بالتكنولوجيا الجديدة، التعرف على مصادر المعرفة الخاصة بالتكنولوجيا الجديدة، الوقوف على مستوى نشر التكنولوجيا الجديدة، الوقوف على دور الإرشاد الزراعي في نشر الوعي بين مربي الماشية، وصف طبيعة العلاقة بين مستوى المعرفة والمتغيرات المستقلة المدروسة، تحديد العوامل المؤثرة على مستوى معرفة مربي الماشية بالتكنولوجيا الجديدة، التعرف على معوقات نشر التكنولوجيا الجديدة. أجري البحث ببعض المناطق الريفية بمحافظة المنوفية، وتم اختيار ثلاث مراكز هي (أشمون، شبين الكوم، ومنوف) لانتشار تربية المواشي بهم، وتم اختيار أربع قرى منهم بطريقة عشوائية وهم (قرية شنشور، وقرية شوشاي) التابعين لمركز أشمون، الماي التابعة لمركز شبين الكوم، وسرس الليان التابعة لمركز منوف، وتم تحليل البيانات باستخدام البرنامج الإحصائي SPSS، حيث استخدمت عدة أساليب إحصائية في تحليل البيانات بعضها وصفيا والآخر استدلاليا، وكانت أهم نتائج الدراسة هي: أن (79,9%) لديهم مستوى معرفة متوسط بالتكنولوجيا الجديدة، كما أوضحت النتائج أن (78.8%) لديهم مستوى نشر متوسط للتكنولوجيا الجديدة، وأشارت النتائج أن دور الإرشاد الزراعي منخفض في نشر الوعي لدى الغالبية العظمى من المبحوثين (88,7%)، وأشارت نتائج تحليل الارتباط إلى وجود علاقة ارتباطية معنوية موجبة بين مستوى معرفة المبحوثين وبين المتغيرات المستقلة المدروسة التالية: قيادة الرأي، إدراك الأنشطة والجهود الإرشادية، تعقيد وصعوبة المبتكر، القنوات الاتصالية، مصادر المعلومات، الاتصال الإرشادي، تجريب المبتكر، المشاركة الاجتماعية، حجم الحيازة الحيوانية، إدراك نشاط المرشد، وضوح المبتكر، حجم الحيازة الزراعية، وأثر البيئة المحيطة.